Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
Growing
The company is in a growing phase, with the latest annual income totaling USD 455.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 455.00K.
Overvalued
The company’s latest PE is -1.03, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 97.84M shares, increasing 0.04% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 6.35M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.73.